2022
Regulatory T Cells: Liquid and Living Precision Medicine for the Future of VCA
Kauke-Navarro M, Knoedler S, Panayi AC, Knoedler L, Noel OF, Pomahac B. Regulatory T Cells: Liquid and Living Precision Medicine for the Future of VCA. Transplantation 2022, 107: 86-97. PMID: 36210500, DOI: 10.1097/tp.0000000000004342.Peer-Reviewed Original ResearchConceptsSolid organ transplantationOrgan transplantationSide effectsField of VCAMedication side effectsBeneficial clinical effectsChimeric antigen receptorSevere side effectsRisk of infectionT cell receptorMaintenance immunosupressionMetabolic complicationsClinical effectsTransplant rejectionLifelong immunosuppressionImmune cellsTregsComposite allotransplantationSpecific antigenTherapeutic efficacyAntigen receptorStable levelPrecision medicineImmune system mechanismsImmunotolerance
2021
Immunoregulatory and lipid presentation pathways are upregulated in human face transplant rejection
Win T, Crisler W, Dyring-Andersen B, Lopdrup R, Teague J, Zhan Q, Barrera V, Sui S, Tasigiorgos S, Murakami N, Chandraker A, Tullius S, Pomahac B, Riella L, Clark R. Immunoregulatory and lipid presentation pathways are upregulated in human face transplant rejection. Journal Of Clinical Investigation 2021, 131 PMID: 33667197, PMCID: PMC8262560, DOI: 10.1172/jci135166.Peer-Reviewed Original ResearchConceptsVCA rejectionTransplant rejectionT cellsTissue injuryGene expression profilingAntigen-presenting cell activationT-cell receptor sequencingSolid organ transplantsCell receptor sequencingT cell activation pathwaysAntigen-specific activationProliferative T cellsCell activation pathwaysNovo Nordisk FoundationAmerican SocietyExpression profilingFace transplant patientsTransplant patientsImmunologic pathwaysImmunoregulatory networkSkin biopsiesImmunomodulatory pathwaysLimb transplantsLundbeck FoundationTransplant Research
2019
Blood proteome profiling using aptamer-based technology for rejection biomarker discovery in transplantation
Shubin A, Kollar B, Dillon S, Pomahac B, Libermann T, Riella L. Blood proteome profiling using aptamer-based technology for rejection biomarker discovery in transplantation. Scientific Data 2019, 6: 314. PMID: 31819064, PMCID: PMC6901551, DOI: 10.1038/s41597-019-0324-y.Peer-Reviewed Original ResearchConceptsDevastating facial injuriesSevere rejection episodesAcute transplant rejectionType of transplantationPeripheral blood serumSOMAscan proteomics platformSatisfactory treatment optionAcute rejectionRejection episodesTransplant statusTransplantation centersTransplant rejectionTreatment optionsBiomarker discoverySkin biopsiesClinical dataHigh riskFacial injuriesInvasive biomarkersTransplantationAptamer-based technologiesFace transplantationPatientsBlood serumSerum proteins1013 Immunoregulatory and lipid presentation pathways are upregulated in human face transplant rejection
Win T, Dyring-Andersen B, Lopdrup R, Teague J, Barrera V, Sui S, Murakami N, Chandraker A, Tullius S, Pomahac B, Riella L, Clark R. 1013 Immunoregulatory and lipid presentation pathways are upregulated in human face transplant rejection. Journal Of Investigative Dermatology 2019, 139: s175. DOI: 10.1016/j.jid.2019.03.1089.Peer-Reviewed Original ResearchTransplant rejectionPresentation pathway
2018
Increased levels of circulating MMP3 correlate with severe rejection in face transplantation
Kollar B, Shubin A, Borges T, Tasigiorgos S, Win T, Lian C, Dillon S, Gu X, Wyrobnik I, Murphy G, Pomahac B, Libermann T, Riella L. Increased levels of circulating MMP3 correlate with severe rejection in face transplantation. Scientific Reports 2018, 8: 14915. PMID: 30297859, PMCID: PMC6175842, DOI: 10.1038/s41598-018-33272-7.Peer-Reviewed Original ResearchConceptsSevere rejectionFace transplantationLarge independent patient cohortsAcute rejection episodesAnti-rejection treatmentFirst postoperative yearLongitudinal serum samplesNon-invasive candidate biomarkersViable treatment optionSOMAscan proteomics platformIndependent patient cohortsFace transplant recipientsRejection episodesPostoperative yearTransplant recipientsDevastating injuriesMMP3 levelsTransplant rejectionHistological gradePatient cohortTreatment optionsSurrogate markerMMP3 proteinCandidate biomarkersTransplantation
2014
Biomarker evaluation of face transplant rejection: association of donor T cells with target cell injury
Lian C, Bueno E, Granter S, Laga A, Saavedra A, Lin W, Susa J, Zhan Q, Chandraker A, Tullius S, Pomahac B, Murphy G. Biomarker evaluation of face transplant rejection: association of donor T cells with target cell injury. Modern Pathology 2014, 27: 788-799. PMID: 24434898, DOI: 10.1038/modpathol.2013.249.Peer-Reviewed Original ResearchConceptsTarget cell injurySkin allograft rejectionDonor T cellsRecipient T cellsT cellsCell injuryAllograft rejectionMemory T cell subsetsAssessment of rejectionFacial transplantT cell subsetsPotential translational significanceImmune cell interactionsRejection episodesClinicopathological assessmentFollicular infundibulumHistologic evidenceSerial biopsiesTransplant rejectionEpidermal targetsDonor originImmune cellsSequential biopsiesDermal microvesselsTranslational significance